scorecardresearch
Add as a preferred source on Google
Thursday, November 6, 2025
TopicRemdesivir

Topic: Remdesivir

Approved by US, rejected by WHO — science of remdesivir & why it has turned controversial

The controversy around remdesivir use stems from divergent claims about its efficacy among patients, and appears to centre on the stage at which it should be administered to patients.

Busting Covid myths on plasma therapy and remdesivir, and what India’s falling numbers mean

In episode 602 of #CutTheClutter, Shekhar Gupta analyses India's declining Covid numbers, and explains the science behind remdesivir and plasma therapy.

ICMR recommends dropping Interferon, adding cancer drug Acalabrutinib to WHO Solidarity trial

ICMR has submitted a proposal to the Modi govt recommending the cancer drug developed by AstraZeneca, which apparently improved clinical outcomes of patients with severe Covid-19.

Remdesivir is first Covid drug to get US FDA approval

The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients.

ICMR recalls statement that said WHO’s Solidarity Trial plans to continue testing remdesivir

Remdesivir, along with HCQ, lopinavir and interferon, have shown no benefits on Covid patients in WHO's multi-national Solidarity Trial.

Gilead questions trial design after WHO says its remdesivir is ineffective against Covid

In a statement issued Thursday, Gilead Sciences noted that Solidarity trial's interim findings on remdesivir have 'not undergone the rigorous review'.

Remdesivir, HCQ, lopinavir & interferon have no effect on Covid patients — Solidarity trial

In a paper on the interim findings on the four drugs, WHO's Solidarity trial researchers in 30 countries return a clear negative.

AYUSH scientists slam IMA for calling their systems ‘unscientific’, question HCQ & remdesivir

Doctors’ body had questioned health minister for promoting AYUSH, but AYUSH scientists ask why HCQ was used despite no evidence that it’s effective.

Ashwagandha, kadha, guduchi — Modi govt issues official ayurveda protocol for mild Covid

A selection of the best news reports, analysis and opinions published by ThePrint this week.

RSS affiliate tells Modi govt to cancel remdesivir patent & act against ‘greedy’ pharma MNCs

In a letter to Modi, Swadeshi Jagran Manch requested the PM to cancel the patent on remedsivir, which it said was granted 'against the provisions of Indian Patents Act'.

On Camera

Indians have a complicated relationship with Zohran Mamdani

Mamdani’s politics feels unusual compared to India’s current climate. He unapologetically foregrounds Muslim identity at a time when doing so in India invites scrutiny.

What does NCLAT order mean for data-sharing ban, penalty imposed by CCI on Meta & WhatsApp

On 4 November 2025, NCLAT bench, comprising Chairperson Justice Ashok Bhushan and Member Arun Baroka, noted that WhatsApp and Meta are distinct legal entities.

‘Let them see’: Putin says new nuclear-powered missiles in the making, in message to Washington

At a ceremony felicitating Russian military engineers, Putin highlights Moscow’s 'parity' in defence technologies for the next century.

Trump’s trade wars have rewritten powerplay, but India didn’t get the memo

This world is being restructured and redrawn by one man, and what’s his power? It’s not his formidable military. It’s trade. With China, it turned on him.